EASD 2026 Preview: Milan Diabetes Catalysts
EASD 2026 is the next major European diabetes catalyst meeting: the 62nd Annual Meeting of the European Association for the Study of Diabetes runs 28 September to 2 October 2026 at Allianz MiCo in Milan. For BD teams, Milan is where incretin, insulin, and metabolic-liver stories collide with fresh EU regulatory context—not a place to invent podium winners before abstracts post.
Contents10 sections
Key Takeaways
- EASD 2026 is scheduled for 28 September–2 October 2026 at Allianz MiCo, Milan.
- Official timing separates industry sessions (28 Sep–2 Oct) from the scientific programme (29 Sep–2 Oct) and exhibition (29 Sep–1 Oct).
- Early registration on the EASD site ran through 21 July 2026; abstract submission is closed per EASD notices.
- EU diabetes BD prep should pair congress science with recent EMA CHMP activity on insulin aspart and liraglutide products.
EASD 2026 at a glance
| Field | Detail |
|---|---|
| Congress | EASD 2026 (62nd Annual Meeting) |
| Dates | 28 September–2 October 2026 |
| Venue | Allianz MiCo – Milan Convention Centre, Milan, Italy |
| Scientific programme | 29 September–2 October 2026 (CEST) |
| Industry sessions | 28 September–2 October 2026 |
| Regional hub | Europe Events |
What is on the EASD 2026 agenda?
EASD’s official 2026 meeting page describes hundreds of presentations spanning keynotes, symposia, and oral sessions in basic and clinical diabetes research. Programme-at-a-glance materials circulating for Milan already flag thematic blocks such as early combination versus stepwise therapy, MASLD directions, disease-modifying drug use in type 2 diabetes, and an EASD–ADA joint implementation session—useful for agenda mapping even before individual late-breakers publish.
Operationally, BD calendars should note the split: industry programming starts 28 September, while the core scientific programme runs 29 September–2 October, with the exhibition listed for 29 September–1 October. That cadence shapes when medical booth traffic and when Hot Line-style rooms typically open.
Which diabetes themes matter for partnering?
Without inventing company-specific 2026 podium slots that sponsors have not confirmed on wire, the highest-signal prep is thematic. NIDDK’s public diabetes overview remains a clean primer for non-clinical stakeholders joining Milan diligence: NIDDK diabetes information hub.
- Incretin / dual-agonist competitive intensity and combination sequencing.
- Insulin biosimilar and rapid-acting analogue market access in Europe.
- MASLD / MASH adjacency to type 2 diabetes franchises.
- Implementation science (EASD–ADA framing) that influences guideline language buyers quote in contracts.
ClinicalTrials.gov remains the place to verify any specific asset a sponsor later claims will appear in Milan—do not accept conference marketing email alone as evidence of a late-breaker.
How should EU regulatory context shape EASD 2026 prep?
Congress science and CHMP outcomes move on different clocks, but BD memos should keep both tabs open. On 26 February 2026, CHMP adopted a positive opinion for Dazparda (insulin aspart), a biosimilar to NovoRapid, later authorised in the EU. On 21 May 2026, CHMP adopted a positive opinion for Liraglutide STADA for insufficiently controlled type 2 diabetes in patients aged 10 years and above under the stated indication conditions.
Those decisions do not forecast which companies win Milan headlines. They do show that EU reviewers remain active on insulin analogues and GLP-1 products—exactly the classes that typically dominate EASD industry theatres and secondary endpoints discussions.
How should BD teams run the Milan week?
Treat EASD 2026 as a four-plus-day partnering sprint with science as the filter, not the only output.
- Lock MiCo logistics and industry-theatre bookings before scientific late-breaker lists finalize.
- Build a living watchlist of sponsor wires that explicitly say “EASD 2026” or “62nd EASD Annual Meeting.”
- Pair each candidate asset with its ClinicalTrials.gov NCT and latest EMA/FDA label status.
- Separate confirmed abstract titles from rumor; delete unsourceable efficacy numbers.
For trial-method grounding while you wait on Milan abstracts, registry pages such as large Phase 3 diabetes studies on ClinicalTrials.gov remain the primary way to validate endpoints a company later claims.
What remains unproven before EASD 2026?
EASD has not, in the materials reviewed here, published a complete late-breaking clinical trial roster with company-level winners. Do not invent HbA1c deltas, weight-loss percentages, MASH biopsy rates, or deal values. Early-registration deadlines that have already passed do not change the scientific embargo calendar.
Related NovaPharma coverage
- CHMP positive opinions on diabetes drugs (Q3 2026 context)
- Ozempic pill access and type 2 diabetes pricing context
- EASD 2026 event hub
- Europe Events listing
Frequently Asked Questions
When and where is EASD 2026?
The 62nd EASD Annual Meeting runs 28 September to 2 October 2026 at Allianz MiCo in Milan, Italy, per the official EASD 2026 page.
What should BD teams watch at EASD 2026?
Watch the scientific programme from 29 September, industry sessions across 28 September–2 October, and late-breaking diabetes / MASLD / combination-therapy themes once abstracts publish.
How does EMA diabetes regulation frame EASD 2026?
Recent CHMP-positive diabetes products such as Dazparda (insulin aspart biosimilar) and Liraglutide STADA show EU label momentum that BD teams should map against congress science.
Primary Sources
This article follows our editorial standards. Report a correction via editorial contact.
